Purpose
The purpose of this study was to investigate the effect of 21-gene recurrence score (RS) on predicting prognosis and chemotherapy decision in node micrometastases (N1mi) breast invasive ductal carcinoma (IDC).
Methods
Patients with stage T1-2N1mi and estrogen receptor-positive IDC diagnosed between 2004 and 2015 were included. The associations of 21-gene RS with breast cancer-specific survival (BCSS), chemotherapy decision, and benefit of chemotherapy were analyzed.
Results
We identified 4,758 patients including 1,403 patients (29.5%) treated with adjuvant chemotherapy. In the traditional RS cutoffs, 2,831 (59.5%), 1,634 (34.3%), and 293 (6.2%) patients were in the low-, intermediate-, and high-risk RS groups, respectively. In 3,853 patients with human epidermal growth factor receptor-2 (HER2) status available, most patients were HER2-negative disease (98.3%). A higher RS was independently related to chemotherapy receipt, and 14.0%, 47.7%, and 77.8% of patients in the low-, intermediate-, and high-risk RS groups received chemotherapy, respectively. The multivariate analysis indicated that a higher RS was related to worse BCSS (p < 0.001). The 5-year BCSS rates were 99.3%, 97.4%, and 91.9% in patients with low-, intermediate-, and high-risk RS groups, respectively (p < 0.001). However, chemotherapy receipt did not correlate with better BCSS in low-, intermediate-, or high-risk RS groups. There were similar trends using Trial Assigning Individualized Options for Treatment RS cutoffs.
Conclusion
The 21-gene RS does predict outcome and impact on chemotherapy decision of N1mi breast IDC. Large cohort and long-term outcomes studies are needed to identify the effects of chemotherapy in N1mi patients by different 21-gene RS groups.
Citations
Citations to this article as recorded by
21-gene recurrence score predictive of the benefit of postoperative radiotherapy after breast-conserving surgery for elderly patients with T1N0 and luminal breast cancer Run-Jie Wang, Hai-Ying Liu, Lin-Feng Guo, De Yu, San-Gang Wu Breast Cancer.2024; 31(6): 1156. CrossRef
Evaluation of adjuvant therapy for T1-2N1miM0 breast cancer without further axillary lymph node dissection Baiyu Li, Jianbo Liu, Guangyin Wu, Qingyao Zhu, Shundong Cang Frontiers in Surgery.2023;[Epub] CrossRef
Effectiveness of post-mastectomy adjuvant chemotherapy for the treatment of patients with prognostic stage IB breast cancer: A SEER-based study HongMei Wang, Yi Peng, Jianbin Wu, ZhuangWei Chen, HuaLe Zhang Asian Journal of Surgery.2023; 46(9): 3634. CrossRef
Comparison of 21-gene assay and St.Gallen International Expert Consensus in the treatment decision for patients with early invasive breast cancers Ming Luo, Fu Li, Ka Su, Huiming Yuan, Jian Zeng Cancer Biology & Therapy.2020; 21(2): 108. CrossRef
Oncotype DX Breast Recurrence Score®: A Review of its Use in Early-Stage Breast Cancer Yahiya Y. Syed Molecular Diagnosis & Therapy.2020; 24(5): 621. CrossRef
Purpose
The study aimed to search and identify genes that were differentially expressed in breast cancer, and their roles in cancer growth and progression.
Materials and Methods
The Gene Expression Omnibus (Oncomine) and The Cancer Genome Atlas databases (https://cancergenome.nih.gov/) were screened for genes that were expressed differentially in breast cancer and were closely related to a poor prognosis. Gene expressions were verified by quantitative real-time polymerase chain reaction, and genes were knocked down by a lentivirus-based system. Cell growth and motility were evaluated and in vivo nude mice were used to confirm the in vitro roles of genes. Markers of epithelial-to-mesenchymal transition and the associations of KIF11 with the classical cancer signaling pathways were detected by Western blot.
Results
A series of genes expressed differentially in patients with breast cancer. The prognosis associated with high KIF11 expression was poor, and the expression of KIF11 increased significantly in high stage and malignant tumor cells. Inhibiting KIF11 expression in lentivirus-suppressed cells revealed that KIF11 inhibition significantly reduced cell viability and colony formation, inhibited migration and invasion, but promoted apoptosis. The sizes and weights of KIF11-inhibited tumors in nude mice were significantly lower than in the negative controls. Western blot showed that E-cadherin in breast cancer was significantly upregulated in KIF-inhibited cells and tumor tissues, whereas N-cadherin and vimentin were significantly downregulated. BT549 and MDA231 cells with KIF11 knockdown exhibited decreased ERK, AMPK, AKT, and CREB phosphorylation.
Conclusion
KIF11 acts as a potential oncogene that regulates the development and progression of breast cancer.
Citations
Citations to this article as recorded by
HELLS Knockdown Inhibits the Malignant Progression of Lung Adenocarcinoma Via Blocking Akt/CREB Pathway by Downregulating KIF11 Gang Yang, Jinsong Fu, Jiawei Wang, Mei Ding Molecular Biotechnology.2025; 67(2): 548. CrossRef
Identification of potential biomarkers for 2022 Mpox virus infection: a transcriptomic network analysis and machine learning approach Joy Prokash Debnath, Kabir Hossen, Sabrina Bintay Sayed, Md. Sayeam Khandaker, Preonath Chondrow Dev, Saifuddin Sarker, Tanvir Hossain Scientific Reports.2025;[Epub] CrossRef
GPSM1 interacts and cooperates with MMP19 to promote proliferation and EMT in colorectal cancer cells Lu Wang, Na Li, Yang Chen, Yehua Qiao, Yaolin Song, Xiangyan Zhang, Han Zhao, Wenwen Ran, Guangqi Li, Xiaoming Xing Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.2025; 1872(3): 119903. CrossRef
Identification and validation of the important role of KIF11 in the development and progression of endometrial cancer Biying Wang, Lunmin Bao, Xiaoduo Li, Guang Sun, Wu Yang, Nanzi Xie, Ling Lei, Wei Chen, Hailong Zhang, Man Chen, Xing Zhao, Xiufang Wan, Rui Yuan, Hongmei Jiang Journal of Translational Medicine.2025;[Epub] CrossRef
Integrative analysis of T cell-mediated tumor killing-related genes reveals KIF11 as a novel therapeutic target in esophageal squamous cell carcinoma Xinxin Cheng, Huihui Zhao, Zhangwang Li, Liping Yan, Qingjie Min, Qingnan Wu, Qimin Zhan Journal of Translational Medicine.2025;[Epub] CrossRef
KIF11 and KIF14 Are a Novel Potential Prognostic Biomarker in Patients with Endometrioid Carcinoma Paulina Antosik, Justyna Durślewicz, Marta Smolińska-Świtała, Jonasz Podemski, Edyta Podemska, Izabela Neska-Długosz, Jakub Jóźwicki, Dariusz Grzanka Cancers.2025; 17(5): 804. CrossRef
Identification of Hub Genes and Potential Drugs in Neurofibromatosis 1: An Integrated Bioinformatics Analysis Zoha Adnan, Muhammad Asif Rasheed, Sami Ullah Khan, Areeba Irfan, Fuad A. Awwad, Emad A. A. Ismail, M. Ijaz Khan, Nargiza Kamolova Journal of Computational Biophysics and Chemistry.2025; 24(03): 359. CrossRef
Targeting Eg5 using Arry520 combats gastric cancer by inducing monopolar spindles Na He, Xinyuan Wei, Ruofei Sun, Gengyuan Zhang, Jie Zhao, Xiangyan Jiang, Bo Long, Zeyuan Yu, Wengui Shi, Zuoyi Jiao Gene.2025; 955: 149458. CrossRef
The role of kinesin family members in hepatobiliary carcinomas: from bench to bedside Kai Zhao, Xiangyu Li, Yunxiang Feng, Jianming Wang, Wei Yao Biomarker Research.2024;[Epub] CrossRef
Mitotic Functions and Characters of KIF11 in Cancers Wanting Gao, Junjie Lu, Zitao Yang, Enmin Li, Yufei Cao, Lei Xie Biomolecules.2024; 14(4): 386. CrossRef
Kinesin 26B modulates M2 polarization of macrophage by activating cancer-associated fibroblasts to aggravate gastric cancer occurrence and metastasis Lian-Meng Huang, Ming-Jin Zhang World Journal of Gastroenterology.2024; 30(20): 2689. CrossRef
Di-(2-ethylhexyl) phthalate promotes benign prostatic hyperplasia through KIF11-Wnt/β-catenin signaling pathway Pan Song, Dong Lv, Luchen Yang, Jing Zhou, Xin Yan, Zhenghuan Liu, Kai Ma, Yunfei Yu, Xiaoyang Liu, Qiang Dong Ecotoxicology and Environmental Safety.2024; 281: 116602. CrossRef
Transcriptomic profiles‐based approach to decode the role of miR‐122 in triple negative breast cancer Mauricio Flores Fortis, Isidro X. Perez Añorve, Oscar del Moral Hernandez, Nicolas Villegas, Elena Arechaga Ocampo Genes, Chromosomes and Cancer.2023; 62(7): 392. CrossRef
ASPM promotes migration and invasion of anaplastic thyroid carcinoma by stabilizing KIF11 Qilu Fang, Qinglin Li, Yajun Qi, Zongfu Pan, Tingting Feng, Wenxiu Xin Cell Biology International.2023; 47(7): 1209. CrossRef
Effect of KIF15 as a promoter role in the progression of osteosarcoma based on TCGA database Jin Qian, Laicheng Zou, Xiao Han, Zhen Zhang, Qing Qiu, Liulong Zhu, Zhenyu Bian Soft Computing.2023;[Epub] CrossRef
KIF11 serves as a cell cycle mediator in childhood acute lymphoblastic leukemia Liwen Zhu, Chuqin Chen, Meiyun Kang, Xiaopeng Ma, Xiaoyan Sun, Yao Xue, Yongjun Fang Journal of Cancer Research and Clinical Oncology.2023; 149(17): 15609. CrossRef
Protooncogenic Role of ARHGAP11A and ARHGAP11B in Invasive Ductal Carcinoma: Two Promising Breast Cancer Biomarkers Y. Naeimzadeh, S. Ilbeigi, H. Dastsooz, M. Rafiee Monjezi, Y. Mansoori, S. M. B. Tabei, Yuan Li BioMed Research International.2023;[Epub] CrossRef
Upregulation of KIF11 in TP53 Mutant Glioma Promotes Tumor Stemness and Drug Resistance Bin Liu, Gang Zhang, Shukun Cui, Guoliang Du Cellular and Molecular Neurobiology.2022; 42(5): 1477. CrossRef
High KIF11 expression is associated with poor outcome of NSCLC Junhui Liu, Yubin Tian, Lei Yi, Zhaojia Gao, Ming Lou, Kai Yuan Tumori Journal.2022; 108(1): 40. CrossRef
Negative Modulation of the Angiogenic Cascade Induced by Allosteric Kinesin Eg5 Inhibitors in a Gastric Adenocarcinoma In Vitro Model Alessia Ricci, Marialucia Gallorini, Donatella Del Bufalo, Amelia Cataldi, Ilaria D’Agostino, Simone Carradori, Susi Zara Molecules.2022; 27(3): 957. CrossRef
Oncological drug discovery: AI meets structure-based computational research Marina Gorostiola González, Antonius P.A. Janssen, Adriaan P. IJzerman, Laura H. Heitman, Gerard J.P. van Westen Drug Discovery Today.2022; 27(6): 1661. CrossRef
Targeting kinesin family member 21B by miR-132-3p represses cell proliferation, migration and invasion in gastric cancer Bingtian Liu, Ling Qiang, Bingxin Guan, Zhipeng Ji Bioengineered.2022; 13(4): 9006. CrossRef
KIF11 manipulates SREBP2‐dependent mevalonate cross talk to promote tumor progression in pancreatic ductal adenocarcinoma Xiang Gu, Qunshan Zhu, Guangyu Tian, Wenbo Song, Tao Wang, Ali Wang, Xiaojun Chen, Songbing Qin Cancer Medicine.2022; 11(17): 3282. CrossRef
KIF11 Is a Promising Therapeutic Target for Thyroid Cancer Treatment Yue Han, Jing Chen, Dianjun Wei, Baoxi Wang, Shakeel Ahmad Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef
Kinesin Eg5 Selective Inhibition by Newly Synthesized Molecules as an Alternative Approach to Counteract Breast Cancer Progression: An In Vitro Study Alessia Ricci, Amelia Cataldi, Simone Carradori, Susi Zara Biology.2022; 11(10): 1450. CrossRef
Comprehensive analysis of prognostic value, relationship to cell cycle, immune infiltration and m6A modification of ZSCAN20 in hepatocellular carcinoma Fang Jiayu, Yike Jiang, Xuanrui Zhou, Minqin Zhou, Jingying Pan, Yun Ke, Jing Zhen, Da Huang, Weifan Jiang Aging.2022;[Epub] CrossRef
Integrative analysis of transcriptional profile reveals LINC00052 as a suppressor of breast cancer cell migration Jose Manuel Sanchez-Lopez, Edna Ayerim Mandujano-Tinoco, Alfredo Garcia-Venzor, Laura Fatima Lozada-Rodriguez, Cecilia Zampedri, Salvador Uribe-Carvajal, Jorge Melendez-Zajgla, Vilma Maldonado, Floria Lizarraga Cancer Biomarkers.2021; 30(4): 365. CrossRef
Identification of the Hub Genes Associated with the Prognosis of Ovarian Cancer Patients via Integrated Bioinformatics Analysis and Experimental Validation Yuzi Zhao, Jie Pi, Lihua Liu, Wenjie Yan, Shufang Ma, Li Hong Cancer Management and Research.2021; Volume 13: 707. CrossRef
Overexpression of EZH2/NSD2 Histone Methyltransferase Axis Predicts Poor Prognosis and Accelerates Tumor Progression in Triple-Negative Breast Cancer Bo Gao, Xiumin Liu, Zhengjin Li, Lixian Zhao, Yun Pan Frontiers in Oncology.2021;[Epub] CrossRef
KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo Gerhard Jungwirth, Tao Yu, Junguo Cao, Montadar Alaa Eddine, Mahmoud Moustafa, Rolf Warta, Juergen Debus, Andreas Unterberg, Amir Abdollahi, Christel Herold-Mende Cancer Letters.2021; 506: 1. CrossRef
KIF11 Serves as an Independent Prognostic Factor and Therapeutic Target for Patients With Lung Adenocarcinoma Zhaodong Li, Bingxin Yu, Fangyuan Qi, Fan Li Frontiers in Oncology.2021;[Epub] CrossRef
Dauricine inhibits human pancreatic carcinoma cell proliferation through regulating miRNAs Ling Jiang, Tianzhu Guo, Ying Jiang, Ping Liu, Yun Bai Molecular Omics.2021; 17(4): 630. CrossRef
ASPM combined with KIF11 promotes the malignant progression of hepatocellular carcinoma via the Wnt/β‑catenin signaling pathway Bin Wu, Chunyang Hu, Lianbao Kong Experimental and Therapeutic Medicine.2021;[Epub] CrossRef
Screening and predicted value of potential biomarkers for breast cancer using bioinformatics analysis Xiaoyu Zeng, Gaoli Shi, Qiankun He, Pingping Zhu Scientific Reports.2021;[Epub] CrossRef
Screening and identification of hub genes in bladder cancer by bioinformatics analysis and KIF11 is a potential prognostic biomarker Xiao-Cong Mo, Zi-Tong Zhang, Meng-Jia Song, Zi-Qi Zhou, Jian-Xiong Zeng, Yu-Fei Du, Feng-Ze Sun, Jie-Ying Yang, Jun-Yi He, Yue Huang, Jian-Chuan Xia, De-Sheng Weng Oncology Letters.2021;[Epub] CrossRef
Kinesin superfamily proteins: roles in osteosarcoma Yao Lu, Tao Song, Xue Xue, Gaolu Cao, Panpan Huang Frontiers in Bioscience-Landmark.2021;[Epub] CrossRef
KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors Ernest Terribas, Marco Fernández, Helena Mazuelas, Juana Fernández-Rodríguez, Josep Biayna, Ignacio Blanco, Gabriela Bernal, Irma Ramos-Oliver, Craig Thomas, Rajiv Guha, Xiaohu Zhang, Bernat Gel, Cleofé Romagosa, Marc Ferrer, Conxi Lázaro, Eduard Serra Neuro-Oncology Advances.2020; 2(Supplement): i62. CrossRef
Kinesin family member 11 is a potential therapeutic target and is suppressed by microRNA‐30a in breast cancer Benfang Wang, Jianjiang Yu, Zhenjiang Sun, Frank Luh, Dandan Lin, Ying Shen, Ting Wang, Qi Zhang, Xiyong Liu Molecular Carcinogenesis.2020; 59(8): 908. CrossRef
Development and validation of a five‐gene model to predict postoperative brain metastasis in operable lung adenocarcinoma Fangqiu Fu, Yang Zhang, Zhendong Gao, Yue Zhao, Zhexu Wen, Han Han, Yuan Li, Haiquan Chen International Journal of Cancer.2020; 147(2): 584. CrossRef
GSG2 (Haspin) promotes development and progression of bladder cancer through targeting KIF15 (Kinase-12) Yuhao Chen, Dian Fu, Hai Zhao, Wen Cheng, Feng Xu Aging.2020; 12(10): 8858. CrossRef
Identification of Metastasis-Associated Biomarkers in Synovial Sarcoma Using Bioinformatics Analysis Yan Song, Xiaoli Liu, Fang Wang, Xiaoying Wang, Guanghui Cheng, Changliang Peng Frontiers in Genetics.2020;[Epub] CrossRef
Identification of Hub Genes in Anaplastic Thyroid Carcinoma: Evidence From Bioinformatics Analysis Liqi Li, Mingjie Zhu, Hu Huang, Junqiang Wu, Dong Meng Technology in Cancer Research & Treatment.2020;[Epub] CrossRef
Exploration and validation of a novel prognostic signature based on comprehensive bioinformatics analysis in hepatocellular carcinoma Xiaofei Wang, Jie Qiao, Rongqi Wang Bioscience Reports.2020;[Epub] CrossRef
Identification of candidate biomarkers correlated with the pathogenesis and prognosis of breast cancer via integrated bioinformatics analysis Shuyu Liu, Xinkui Liu, Jiarui Wu, Wei Zhou, Mengwei Ni, Ziqi Meng, Shanshan Jia, Jingyuan Zhang, Siyu Guo, Shan Lu, Yingfei Li Medicine.2020; 99(49): e23153. CrossRef
Identification of Potential Hub Genes Related to Diagnosis and Prognosis of Hepatitis B Virus‐Related Hepatocellular Carcinoma via Integrated Bioinformatics Analysis Yuqin Tang, Yongqiang Zhang, Xun Hu, Nagarajan Raju BioMed Research International.2020;[Epub] CrossRef
KIF14 and KIF23 Promote Cell Proliferation and Chemoresistance in HCC Cells, and Predict Worse Prognosis of Patients with HCC Chunxia Cheng, Xingxing Wu, Yu Shen, Quanxi Li Cancer Management and Research.2020; Volume 12: 13241. CrossRef
Identification of KIF11 as a Novel Target in Meningioma Gerhard Jungwirth, Tao Yu, Mahmoud Moustafa, Carmen Rapp, Rolf Warta, Christine Jungk, Felix Sahm, Steffen Dettling, Klaus Zweckberger, Katrin Lamszus, Christian Senft, Mario Loehr, Almuth F. Keßler, Ralf Ketter, Manfred Westphal, Juergen Debus, Andreas v Cancers.2019; 11(4): 545. CrossRef
Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer Jiayu Sheng, Xiaohong Xue, Ke Jiang Current Molecular Medicine.2019; 19(2): 147. CrossRef
Purpose
This study was conducted to investigate the prognostic value of lymph node ratio (LNR) in
stage II/III breast cancer patients who undergo mastectomy after neoadjuvant chemotherapy.
Materials and Methods
Clinical and pathological data describing stage II/III breast cancer patients were included
in this retrospective study. The primary outcomes were locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS).
Results
Among 277 patients, there were 43 ypN0, 64 ypN1, 89 ypN2, and 81 ypN3 cases. Additionally, there were 43, 57, 92 and 85 cases in the LNR 0, 0.01-0.20, 0.21-0.65, and
> 0.65 groups, respectively. The median follow-up was 49.5 months. Univariate analysis
showed that both ypN stage and LNR were prognostic factors of LRFS, DMFS, DFS, and OS (p < 0.05). Multivariate analysis showed that LNR was an independent prognostic factor of LRFS, DMFS, DFS, and OS (p < 0.05), while ypN stage had no effect on prognosis (p > 0.05).
Conclusion
The integrated use of LNR and ypN may be suitable for evaluation the prognosis of stage
II/III breast cancer patients who undergo mastectomy after neoadjuvant chemotherapy.
Citations
Citations to this article as recorded by
Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study Lingfeng Tang, Linshan Jiang, Xiujie Shu, Yudi Jin, Haochen Yu, Shengchun Liu Scientific Reports.2024;[Epub] CrossRef
Prognostic disparities in young patients based on breast cancer subtype: A population-based study from the SEER database Bing Chen, Xiaojuan Zhang, Yi Liu, Chuandong Wang Medicine.2023; 102(13): e33416. CrossRef
The Effect of Lymph Node Harvest on Prognosis in Locally Advanced Middle-Low Rectal Cancer After Neoadjuvant Chemoradiotherapy Zhuangbin Lin, Xiaobo Li, Jianyuan Song, Rong Zheng, Cheng Chen, Anchuan Li, Benhua Xu Frontiers in Oncology.2022;[Epub] CrossRef
Breast Cancer Patients With Positive Apical or Infraclavicular/Ipsilateral Supraclavicular Lymph Nodes Should Be Excluded in the Application of the Lymph Node Ratio System Zhe Wang, Wei Chong, Huikun Zhang, Xiaoli Liu, Yawen Zhao, Zhifang Guo, Li Fu, Yongjie Ma, Feng Gu Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
Is Pathologic Axillary Staging Valid If Lymph Nodes Are Less than 10 with Axillary Lymph Node Dissection after Neoadjuvant Chemotherapy? Hee Jun Choi, Jai Min Ryu, Jun Ho Lee, Yoonju Bang, Jongwook Oh, Byung-Joo Chae, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Se Kyung Lee, Jonghan Yu Journal of Clinical Medicine.2022; 11(21): 6564. CrossRef
A novel nomogram for predicting locoregional recurrence risk in breast cancer patients treated with neoadjuvant chemotherapy and mastectomy Zhou Huang, Mei Shi, Wei-Hu Wang, Liang-Fang Shen, Yu Tang, Qing-Lin Rong, Li Zhu, Xiao-Bo Huang, Jian Tie, Jia-Yi Chen, Jun Zhang, Hong-Fen Wu, Jing Cheng, Min Liu, Chang-Ying Ma, Shu-Lian Wang, Ye-Xiong Li Radiotherapy and Oncology.2021; 161: 191. CrossRef
Lymph node ratio as best prognostic factor in triple‐negative breast cancer patients with residual disease after neoadjuvant chemotherapy Gabriel A. De la Cruz‐Ku, Diego Chambergo‐Michilot, Bryan Valcarcel, Pamela Rebaza, Mecker Möller, Jhajaira M. Araujo, Daniel Enriquez, Zaida Morante, Cesar Razuri, Renato Luque, Antonella Saavedra, Eduardo Eyzaguirre, Maria Lujan, Naysha Noel, Joseph Pin The Breast Journal.2020; 26(9): 1659. CrossRef
Development and validation of a nomogram incorporating axillary lymph node ratio to predict survival in node-positive breast cancer patients after neoadjuvant chemotherapy Jianguo Lai, Zihao Pan, Peixian Chen, Guolin Ye, Kai Chen, Fengxi Su Japanese Journal of Clinical Oncology.2019; 49(1): 22. CrossRef
Lymph node ratio as an alternative to pN staging for predicting prognosis after neoadjuvant chemotherapy in breast cancer Dong Hui Cho, Soo Youn Bae, Ji Young You, Hong Kyu Kim, Young Woo Chang, Yoo Jin Choi, Sang Uk Woo, Gil Soo Son, Jae Bok Lee, Jeoung Won Bae, Seung Pil Jung The Kaohsiung Journal of Medical Sciences.2018; 34(6): 341. CrossRef
Ganglio secundario como indicador de linfadenectomía axilar en pacientes afectas de cáncer de mama Manel Cremades, Mireia Torres, Montse Solà, Jordi Navinés, Icíar Pascual, Antonio Mariscal, Albert Caballero, Eva Castellà, Miguel Ángel Luna, Joan Francesc Julián Cirugía Española.2017; 95(9): 536. CrossRef
Secondary Node Analysis as an Indicator for Axillary Lymphadenectomy in Breast Cancer Patients Manel Cremades, Mireia Torres, Montse Solà, Jordi Navinés, Icíar Pascual, Antonio Mariscal, Albert Caballero, Eva Castellà, Miguel Ángel Luna, Joan Francesc Julián Cirugía Española (English Edition).2017; 95(9): 536. CrossRef
Risk factors of locoregional relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy following mastectomy and radiotherapy Liang Huang, Sheng Chen, Wentao T. Yang, Zhiming Shao Oncotarget.2017; 8(24): 39703. CrossRef
Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer Jacqueline Tsai, Danielle Bertoni, Tina Hernandez-Boussard, Melinda L. Telli, Irene L. Wapnir Annals of Surgical Oncology.2016; 23(10): 3310. CrossRef
Number of negative lymph nodes as a prognostic factor for ypN0-N1 breast cancer patients undergoing neoadjuvant chemotherapy Fei Xin, Yue Yu, Zheng-Jun Yang, Li-Kun Hou, Jie-Fei Mao, Li Xia, Xin Wang, Xu-Chen Cao Tumor Biology.2016; 37(6): 8445. CrossRef
Purpose The purpose of this study was to assess the value of ovarian ablation using goserelin in premenopausal patients with stage II/III hormone receptor-positive breast cancer without chemotherapy-induced amenorrhea (CIA). Materials and Methods We retrospectively reviewed the data of breast patients treated between October 1999 and November 2007 without CIA. The Kaplan-Meier method was used for calculation of the survival rate. Log rank method and Cox regression analysis were used for univariate and multivariate prognostic analysis. Results The median follow-up period was 61 months. Initially, 353 patients remained without CIA after chemotherapy and 98 among those who received goserelin and tamoxifen (TAM). In univariate analysis, goserelin improved locoregional recurrence-free survival (LRFS) (98.9% vs. 94.1%, p=0.041), distant metastasis-free survival (DMFS) (85.4% vs. 71.9%, p=0.006), disease-free survival (DFS) (85.4% vs. 71.6%, p=0.005), and overall survival (OS) (93.5% vs. 83.5%, p=0.010). In multivariate analysis, goserelin treatment was an independent factor influencing DMFS (hazard ratio [HR], 1.603; 95% confidence interval [CI], 1.228 to 2.092; p=0.001), DFS (HR, 1.606; 95% CI, 1.231 to 2.096; p=0.001), and OS (HR, 3.311; 95% CI, 1.416 to 7.742; p=0.006). In addition, treatment with goserelin resulted in significantly improved LRFS (p=0.039), DMFS (p=0.043), DFS (p=0.036), and OS (p=0.010) in patients aged < 40 years. In patients aged ≥ 40 years, goserelin only improved DMFS (p=0.028) and DFS (p=0.027). Conclusion Ovarian ablation with goserelin plus TAM resulted in significantly improved therapeutic efficacy in premenopausal patients with stage II/III hormone receptor-positive breast cancer without CIA.
Citations
Citations to this article as recorded by
An updated systematic review about various effects of microplastics on cancer: A pharmacological and in-silico based analysis Akmaral Baspakova, Afshin Zare, Roza Suleimenova, Aidar B. Berdygaliev, Bibigul Karimsakova, Kymbat Tussupkaliyeva, Nadiar M. Mussin, Kulyash R. Zhilisbayeva, Nader Tanideh, Amin Tamadon Molecular Aspects of Medicine.2025; 101: 101336. CrossRef
Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis Hamdy A. Azim, Kyrillus S. Shohdy, David F. Kaldas, Loay Kassem, Hatem A. Azim Current Problems in Cancer.2020; 44(6): 100592. CrossRef
Feasibility and efficacy of ultrasonographic and laparoscopic guidance for microwave ablation of clinically normal canine ovaries Valentine D. Verpaalen, J. Brad Case, Michael J. Dark, S. Joel Cardenas-Goicoechea, Matt D. Winter, Sarah E. Boston, Fernando Garcia-Pereira, Alice S. Rhoton-Vlasak, Beau B. Toskich American Journal of Veterinary Research.2020; 81(9): 747. CrossRef
Breast cancer in young patients. Peculiarities of prognosis and adjuvant hormone therapy (a literature review) D. N. Kravchenko, A. A. Parokonnaya, M. I. Nechushkin, E. A. Nikitina, N. D. Hakurinova Tumors of female reproductive system.2018; 14(3): 55. CrossRef
Evaluating the Survival Benefit Following Ovarian Function Suppression in Premenopausal Patients with Hormone Receptor Positive Early Breast Cancer Lin Qiu, Fangmeng Fu, Meng Huang, Yuxiang Lin, Yazhen chen, Minyan Chen, Chuan Wang Scientific Reports.2016;[Epub] CrossRef
Evaluation of a Survivorship Care Plan: Long-Term Use, Care Coordination and Quality of Life in Breast Cancer Survivors Meagan E Brennan, Frances M Boyle, Phyllis N Butow, Andrew J Spillane Breast Cancer Management.2015; 4(3): 145. CrossRef
More Options for Fertility Preservation for Patients With Cancer Pamela N. Munster Journal of Clinical Oncology.2015; 33(22): 2413. CrossRef